Stock Events

Stock Events

Foghorn Therapeutics 

$2.00
14
+$0.00+0%Monday 01:01

Statistics

Day High
2
Day Low
2
52W High
6.07
52W Low
1.95
Volume
-
Avg. Volume
-
Mkt Cap
118.77M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 10Expected
Q3 2025
Q1 2026
Q2 2026
Next
-0.33
-0.26
-0.18
-0.1
Expected EPS
-0.235556
Actual EPS
N/A

Financials

-240.33%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
30.91MRevenue
-74.28MNet Income

Analyst Ratings

$4.00Average Price Target
The highest estimate is ⁦5.00⁩.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
40%
Hold
60%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FHTX.BOATS. It's not an investment recommendation.
Microsoft
4
MSFT
Amazon
4
AMZN
Tesla
4
TSLA
Johnson & Johnson
4
JNJ

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics competes in the precision genetic medicines space, focusing on base editing, a technology with potential overlap in targeting diseases similar to Foghorn's gene traffic control platform.
CRISPR Therapeutics
CRSP
Mkt Cap5.36B
CRISPR Therapeutics is involved in gene editing, a direct competitor to Foghorn's approach to treating cancer and other diseases by manipulating gene expression.
Editas Medicine
EDIT
Mkt Cap402.38M
Editas Medicine operates in the genome editing field, specifically using CRISPR technology to modify genes, competing with Foghorn's gene control therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.72B
Intellia Therapeutics is a leader in CRISPR/Cas9 technology for precise gene editing, competing in the same space as Foghorn's gene manipulation strategies.
Allogene Therapeutics
ALLO
Mkt Cap518.24M
Allogene Therapeutics is focused on allogeneic CAR T cell therapies, a form of cancer treatment that could compete with Foghorn's approach to oncology through gene control.
Fate Therapeutics
FATE
Mkt Cap277.98M
Fate Therapeutics is working on programmed cellular immunotherapies for cancer and immune disorders, competing with Foghorn's gene-focused therapeutic strategies.
Adaptive Biotechnologies
ADPT
Mkt Cap4.52B
Adaptive Biotechnologies is advancing the field of immune-driven medicine, which includes competing technologies for identifying and treating diseases in a manner that could overlap with Foghorn's.
Novartis
NVS
Mkt Cap268B
Novartis is a large pharmaceutical company with a broad portfolio that includes gene therapies and treatments for cancer and genetic diseases, competing on a larger scale with companies like Foghorn.

About

Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
Show More
CEO
ISIN
US3441741077

Listings

BOATS
BOATS
FHTX.BOATS
XNAS
US
FHTX

0 Comments

Share your thoughts

FAQs

What is Foghorn Therapeutics stock price today?▼
The current price of FHTX.BOATS is $2.00 USD — it has increased by +0% in the past 24 hours. Watch Foghorn Therapeutics stock price performance more closely on the chart.
What is Foghorn Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Foghorn Therapeutics stocks are traded under the ticker FHTX.BOATS.
What is Foghorn Therapeutics market cap?▼
Today Foghorn Therapeutics has the market capitalization of 118.77M
When is the next Foghorn Therapeutics earnings date?▼
Foghorn Therapeutics is going to release the next earnings report on November 10, 2026.
What were Foghorn Therapeutics earnings last quarter?▼
FHTX.BOATS earnings for the last quarter are -0.1 USD per share, whereas the estimation was -0.25 USD resulting in a +59.18% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Foghorn Therapeutics revenue for the last year?▼
Foghorn Therapeutics revenue for the last year amounts to 30.91M USD.
What is Foghorn Therapeutics net income for the last year?▼
FHTX.BOATS net income for the last year is -74.28M USD.
In which sector is Foghorn Therapeutics located?▼
Foghorn Therapeutics operates in the Other sector.
When did Foghorn Therapeutics complete a stock split?▼
Foghorn Therapeutics has not had any recent stock splits.